Join the HIV Infection group to help and get support from people like you.
HIV Infection News (Page 8)
Related terms: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome (AIDS), Acute HIV Infection, Acute Retroviral Syndrome, AIDS, AIDS-Related Complex, Chronic Symptomatic HIV Infection, HIV Infection, Acute, HIV Seroconversion Syndrome, Human Immunodeficiency Virus Infection, Primary HIV Infection, HIV, ARC, Acquired Immunodeficiency Syndrome, HIV/AIDS
U.S. Food and Drug Administration Approves New Formulations of Viread for Use by Children Living With HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan 19, 2012 - Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread (tenofovir disoproxil fumarate) in...
U.S. Food and Drug Administration Approves Gilead Sciences' Complera, a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug 10, 2011 - Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera (emtricitabine/rilpivirine/tenofovir...
FDA Approves New HIV Treatment Edurant (rilpivirine)
May 20, 2011 – The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never...
FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy
ROCKLAND, Mass., Nov. 11, 2010 /PRNewswire/ – EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that the U.S. Food and Drug Administration (FDA) has approved Egrifta...
FDA Medwatch Alert: Unapproved Over The Counter Drugs Marketed for Prevention and Treatment of STDs
[Posted 03/06/2008] FDA advised healthcare professionals and consumers that the Agency issued Warning Letters to six U.S. companies and one foreign individual for marketing unapproved and misbranded...
FDA Medwatch Alert: Viramune (nevirapine) - Feb 2, 2004
Boehringer Ingelheim and FDA notified healthcare professionals of new safety information added to the WARNINGS and Boxed Warning for VIRAMUNE. Severe, life-threatening, and in some cases fatal...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Pre-Exposure Prophylaxis, Viral Infection
Related drug support groups
Biktarvy, bictegravir / emtricitabine / tenofovir alafenamide, Genvoya, Triumeq